The promise of antibody-oligonucleotide conjugates for neurological diseases
Bioconjugation Insights · 2025
DOI: 10.18609/bci.2025.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugation Insights, 2025. Verfasst von Kerstin Hofer. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“To fully unlock their potential, there are a few key breakthroughs that are going to be critical.”Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Kerstin Hofer, Science and People Lead, Roche, about the evolving application of antibody-oligonucleotide conjugates in neurology. She highlights their design, delivery challenges across the blood–brain barrier, and potential to transform CNS diseases.
Zitieren
APA
Hofer, K. (2025). The promise of antibody-oligonucleotide conjugates for neurological diseases. Bioconjugation Insights. https://doi.org/10.18609/bci.2025.018
Vancouver
Hofer K. The promise of antibody-oligonucleotide conjugates for neurological diseases. Bioconjugation Insights. 2025. doi:10.18609/bci.2025.018
BibTeX
@article{Hofer2025,
author = {Hofer, Kerstin},
title = {The promise of antibody-oligonucleotide conjugates for neurological diseases},
journal = {Bioconjugation Insights},
year = {2025},
doi = {10.18609/bci.2025.018}
}
EUVIMED